[1]刘 垚,钱有辉.ctDNA检测及靶向药物在非小细胞肺癌中的应用[J].医学信息,2020,33(11):38-41.[doi:10.3969/j.issn.1006-1959.2020.11.013]
　LIU Yao,QIAN You-hui.Detection of ctDNA and Application of Targeted Drugs in Non-small Cell Lung Cancer[J].Medical Information,2020,33(11):38-41.[doi:10.3969/j.issn.1006-1959.2020.11.013]
点击复制

ctDNA检测及靶向药物在非小细胞肺癌中的应用()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年11期
页码:
38-41
栏目:
综述
出版日期:
2020-06-01

文章信息/Info

Title:
Detection of ctDNA and Application of Targeted Drugs in Non-small Cell Lung Cancer
文章编号:
1006-1959（2020）11-0038-04
作者:
刘 垚; 钱有辉
（深圳市第二人民医院心胸外科，广东 深圳 518000）
Author(s):
LIU Yao; QIAN You-hui
(Cardiothoracic Surgery,Shenzhen Second People’s Hospital,Shenzhen 518000,Guangdong,China)
关键词:
非小细胞肺癌; ctDNA检测; 靶向治疗; 酪氨酸激酶抑制剂; 免疫治疗
Keywords:
Non-small cell lung cancer; ctDNA detection; Targeted therapy; Tyrosine kinase inhibitor; Immunotherapy
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2020.11.013
文献标志码:
A
摘要:
非小细胞肺癌（NSCLC）为最常见的肺癌病理类型，约占肺癌总数的 85%。近年来随着对NSCLC生物学及肿瘤发展机制的深入研究，关于NSCLC的早期检测及靶向治疗也取得了明显进步。在早期检测领域，ctDNA检测作为一种非侵入性的NSCLC检测方法受到了广泛的关注，多项研究表明ctDNA有望作为肿瘤细胞检测的可靠生物标志物。在NSCLC治疗领域，多种以酪氨酸激酶抑制剂和免疫治疗为基础的药物逐步推广应用，这些药物显著提高了患者的无进展生存期和总生存率。本文主要从NSCLC的ctDNA检测及靶向治疗展开论述，探讨ctDNA的聚合酶链式反应和测序检测以及靶向治疗和免疫治疗在NSCLC中的应用，旨在为NSCLC诊断及治疗提供参考。
Abstract:
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer pathology, accounting for approximately 85% of the total number of lung cancers. In recent years, with the in-depth study of NSCLC biology and tumor development mechanism, the early detection and targeted therapy of NSCLC has also made significant progress. In the early detection field, ctDNA detection has received widespread attention as a non-invasive NSCLC detection method, and many studies have shown that ctDNA is expected to be a reliable biomarker for tumor cell detection. In the field of NSCLC therapy, a variety of drugs based on tyrosine kinase inhibitors and immunotherapy have been gradually promoted and applied. These drugs have significantly improved the progression-free survival and overall survival of patients. This article mainly discusses the detection of ctDNA and targeted therapy of NSCLC, and discusses the application of polymerase chain reaction and sequencing detection of ctDNA and the application of targeted therapy and immunotherapy in NSCLC.

参考文献/References:

1]秦虹,张科乾,李文花,等.非小细胞肺癌脑转移全脑放疗联合靶向药物治疗系统评价[J].中华肿瘤防治杂志,2015(4):300-304.[2]Santarpia M,Menis J,Chaib I,et al.Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer[J].Expert Review of Clinical Pharmacology,2019,12(9):831-840.[3]杜亚茜,马煜辉,杨长绍,等.非小细胞肺癌患者外周血ctDNA样本中EGFR-T790M基因突变分析[J].实用医学杂志,2017(19):3228-3232.[4]Li Y,Zhang FS,Guo L,et al.Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms[J].Chinese Journal of Pathology,2018,47(12):904-909.[5]Cheng F,Su L,Qian C.Circulating tumor DNA:A promising biomarker in the liquid biopsy of cancer[J].Oncotarget,2016,7(30):48832-48841.[6]Bai H,Xia J,Zhao X,et al.Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer[J].Journal of Clinical Pathology,2019,72(5):379-385. [7]Zhang Q,Nong J,Wang J,et al.Isolation of circulating tumor cells and detection of EGFR mutations in patients with non small cell lung cancer[J].Oncology Letters,2019,17(4):3799-3807. [8]Cabanero M,Tsao M.Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer[J].Current Oncology,2018(25):38.[9]Oxnard GR,Thress KS,Alden RS,et al.Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib(AZD9291)in Advanced Non-Small-Cell Lung Cancer[J].Journal of Clinical Oncology,2016,34(28):3375-3382.[10]Hidenobu,Ishii,Koichi,et al.Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC:Correlation with paired tumor samples[J].Oncotarget,2015(6):30850-30858.[11]Lee JY,Qing X,Xiumin W,et al.Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs:Korean Lung Cancer Consortium(KLCC-12-02)[J].Oncotarget,2016,7(6):6984-6993.[12]Chin RI,Chen K,Usmani A,et al.Detection of Solid Tumor Molecular Residual Disease(MRD)Using Circulating Tumor DNA(ctDNA)[J].Molecular Diagnosis&Therapy,2019(23):311-331.[13]Perdigones N,Murtaza M.Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis[J].Pharmacology&Therapeutics,2017:S0163725817300177.[14]Chabon JJ,Simmons AD,Lovejoy AF,et al.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J].Nature Communications,2016(7):11815.[15]Lin JJ,Riely GJ,Shaw AT.Targeting ALK:Precision Medicine Takes on Drug Resistance[J].Cancer Discovery,2017,7(2):137-155.[16]Chan BA,Hughes BG.Targeted therapy for nonsmall cell lung cancer:current standards and the promise of the future[J].Transl Lung Cancer Res,2015(4):36-54.[17]Garon EB,Rizvi NA,Hui R,et al.Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer[J].New England Journal of Medicine,2015,372(21):2018-2028.[18]Mok TS,Wu YL,Ahn MJ,et al.Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer[J].New England Journal of Medicine,2017,376(7):629-640.[19]Shaw AT,Felip E,Bauer TM,et al.Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement:an international,multicentre,open-label,single-arm first-in-man phase 1 trial[J].The Lancet Oncology,2017:S1470204517306800.[20]Soria JC,Tan DSW,Chiari R,et al.First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study[J].Lancet,2017,389(10072):917-929.[21]Tom P.Nivolumab plus Ipilimumab Versus Sunitinib in Advanced Renal-cell Carcinoma[J].European Urology,2018,74(5):679-680. [22]马薇,罗殿中,陈源,等.PD-L1和PD-1在非小细胞肺癌中的表达及其临床意义[J].实用医学杂志,2011(9):1551-1554.[23]Drilon A,Nagasubramanian R,Blake JF,et al.A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors[J].Cancer Discovery,2017,7(9):CD-17-0507.[24]Reck M,Rodríguez-Abreu D,Robinson AG,et al.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J].N Engl J Med,2016,375(19):1823-1833.[25]Carbone DP,Reck M,Paz-Ares L,et al.First-line nivolumab in stage IV or recurrent non-small-cell lung cancer[J].New England Journal of Medicine,2017,376(25):2415-2426.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Medical Information,2018,31(11):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Medical Information,2018,31(11):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Medical Information,2018,31(11):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Medical Information,2018,31(11):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Medical Information,2019,32(11):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Medical Information,2018,31(11):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Medical Information,2018,31(11):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2018,31(11):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2022,35(11):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Medical Information,2019,32(11):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 1900-01-01